Navigation Links
PAREXEL Ranks as a "Best 5 Outsourcing Company for the Pharmaceutical Industry" by IAOP®
Date:8/24/2011

BOSTON, Aug. 24, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has been included on the "Best 5–Pharmaceutical" industry sublist as part of The International Association of Outsourcing Professionals® (IAOP®) annual ranking The Global Outsourcing 100.

IAOP is in the sixth year of compiling its annual ranking of the world's best outsourcing service providers and advisors. The Global Outsourcing 100 and its sublists are valued references for companies seeking new and expanded relationships with the best companies in the industry. The independently-judged evaluation process considers four key criteria: size and growth, customer experience, depth and breadth of competencies and management capabilities.

"The companies on The Global Outsourcing 100 list are proven leaders and rising stars," said IAOP Chairman Michael Corbett and chair of the judges' panel. "They are the companies to partner with to achieve success and better outsourcing outcomes."

"PAREXEL is honored to be selected for the 'Best 5–Pharmaceutical' industry sublist by the judges of The Global Outsourcing 100," said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International. "The biopharmaceutical industry is exploring new ways to address key time and cost challenges through more effective outsourcing, while achieving more efficient development and commercialization of important new treatments.  At PAREXEL, a key focus is to deliver high levels of quality and best-practice outsourcing models to create significant value for our clients."

About IAOP The International Association of Outsourcing Professionals® (IAOP®) is the global, standard-setting organization and advocate for the outsourcing profession. With more than 110,000 members and affiliates worldwide, IAOP helps companies increase their outsourcing success rate, improve their outsourcing ROI, and expand the opportunities for outsourcing across their businesses. To learn more, visit http://www.iaop.org.

About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public Relations

Kim Baker/Gene CarozzaPAREXEL International

PAN CommunicationsTel: +781-434-4409

Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.com

Email: PAREXEL@pancomm.com
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Closes the Acquisition of ClinPhone
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
6. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
7. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... MA (PRWEB) , ... January 17, 2017 , ... ... the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards ... validating these new tools and assays, and their applicability in drug safety assessment, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court ... decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company ... DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary ...
(Date:1/14/2017)...  The Alliance for Safe Biologic Medicines (ASBM) today ... final guidance on biologic naming: We ... the importance of distinct naming for all biologics, including ... biosimilars will bring to patients, including new treatment options ... of the Guidance dealing with suffix design remains at ...
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in response to several ... new solutions for measurements where traditional cuvette applications are not convenient. For instance, ... oddly-shaped sample that would not fit into a typical cuvette inside a spectrophotometer. ...
Breaking Biology Technology:
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):